CN111826355B - 三分三p450酶及其在制备托品酮中的应用 - Google Patents

三分三p450酶及其在制备托品酮中的应用 Download PDF

Info

Publication number
CN111826355B
CN111826355B CN201910299176.4A CN201910299176A CN111826355B CN 111826355 B CN111826355 B CN 111826355B CN 201910299176 A CN201910299176 A CN 201910299176A CN 111826355 B CN111826355 B CN 111826355B
Authority
CN
China
Prior art keywords
ala
leu
glu
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910299176.4A
Other languages
English (en)
Other versions
CN111826355A (zh
Inventor
肖友利
尤文静
平羽
杨盟权
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Excellence in Molecular Plant Sciences of CAS
Original Assignee
Center for Excellence in Molecular Plant Sciences of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Excellence in Molecular Plant Sciences of CAS filed Critical Center for Excellence in Molecular Plant Sciences of CAS
Priority to CN201910299176.4A priority Critical patent/CN111826355B/zh
Publication of CN111826355A publication Critical patent/CN111826355A/zh
Application granted granted Critical
Publication of CN111826355B publication Critical patent/CN111826355B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0081Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042NADPH-cytochrome P450 reductase (1.6.2.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y106/00Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/02Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12Y106/02004NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/15Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen (1.14.15)
    • C12Y114/15006Cholesterol monooxygenase (side-chain-cleaving) (1.14.15.6), i.e. cytochrome P450scc

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明公开了一种三分三P450酶,该P450酶与细胞色素P450还原酶联合催化能够将4‑(1‑甲基‑2‑吡咯烷基)‑3‑氧代丁酸转化为托品酮。本发明的方法为环境友好型,反应条件温和,具有工业化开发前景。

Description

三分三P450酶及其在制备托品酮中的应用
技术领域
本发明属于生物合成和酶催化技术领域,具体地说,涉及一种三分三P450酶及其在制备托品酮中的应用。
背景技术
托品酮(Tropinone)是一个莨菪烷类生物碱,可用于合成阿托品硫酸盐等药物,其化学名称为8-甲基-8-氮杂双环[3.2.1]辛烷-3-酮,分子结构如式I所示。
Figure BDA0002027643590000011
托品酮目前主要从植物中提取得到。近年来发展的合成生物学技术,通过微生物菌株作为底盘细胞,将目标化合物生物合成途径相关基因导入,实现了植物来源的一些重要药用化合物的异源高效合成(Kotopka BJ,Li Y,Smolke CD.2018.Synthetic biologystrategies toward heterologous phytochemical production.Natural productreports.Li S,Li Y,Smolke CD.2018.Strategies for microbial synthesis of high-value phytochemicals.Nature chemistry 10(4):395-404.),建立托品酮的生物合成方法不仅能弥补化学合成方法的不足之处,同时也为以托品酮为中间体的尼古丁及托品生物碱的途径解析及异源合成提供基础,对于大规模生产莨菪生物碱具有重要的经济意义。
茄科植物三分三(Anisodus acutangulus)是我国特有的产托品类生物碱的资源植物,又名三分七、野箊,其干燥品总生物碱含量高达1.2%,托品生物碱总含量比常见的一些茄科植物如颠茄、莨菪、曼陀罗等都要高(Kai G,Zhang A,Guo Y,Li L,Cui L,Luo X,LiuC,Xiao J.2012.Enhancing the production of tropane alkaloids in transgenicAnisodus acutangulus hairy root cultures by over-expressing tropinonereductase I and hyoscyamine-6β-hydroxylase.Molecular BioSystems 8(11):2883-2890.),并且其转录组数据也被发表(Cui L,Huang F,Zhang D,Lin Y,Liao P,Zong J,KaiG.2015.Transcriptome exploration for further understanding of the tropanealkaloids biosynthesis in Anisodus acutangulus.Molecular Genetics&Genomics290(4):1367-1377.),因此利用独特生物资源优势对于三分三中与托品酮的生物合成有关的酶类的研究非常重要。
众所周知,化学法合成存在环境污染大的问题,导致开发环境友好型的绿色制备工艺很有必要。因此具有反应条件温和、催化效率高、副产物少等优点的生物制备法比如生物酶催化法成为有吸引力和有前途的方法。
发明内容
我们对植物三分三中与托品酮的合成相关的酶类的功能进行了研究,发现一种三分三P450酶(命名为CYP82M3或者AaCYP82M3)分别和三种细胞色素P450还原酶(分别命名为CPR1、CPR2、CPR3或者AaCPR1、AaCPR2、AaCPR3)通过组合配对进行联合催化,可以高效地将式II所示的化合物4-(1-甲基-2-吡咯烷基)-3-氧代丁酸转化成托品酮I,其中P450酶与CPR1或CPR2的组合配对效果尤其突出。
Figure BDA0002027643590000021
这一发现丰富了现有的生物元件库,进一步完善了三分三莨菪生物碱的生物合成途径,可以为莨菪生物碱的途径解析及异源合成提供基础,促进重要药用生物碱的生物合成方法开发。
为了实现托品酮的生物合成,我们从三分三中筛选出一种氨基酸序列为SEQ IDNO:1的三分三细胞色素P450酶CYP82M3;三种细胞色素P450还原酶CPR1-3(氨基酸序列分别为SEQ ID NO:3、SEQ ID NO:5和SEQ ID NO:7),进行体外联合催化底物4-(1-甲基-2-吡咯烷基)-3-氧代丁酸的缩合反应,验证了其功能。由于大肠杆菌和酵母的遗传背景比较清晰,并且遗传操作容易,我们选其作为底盘细胞探究托品酮的体内合成,希望为工业生产托品酮及其衍生的重要生物碱的异源合成提供基础。
其中,SEQ ID NO:1的序列为:
MYDNFPFYDLQIILGVLLTFVVSIILWTRNWKSPKLPPKIPGSWPIIGHLRGFGDGENVPLARTFGKLSDQYGPIFTIKLGMFRYCVINNWEAAKDCFTIHDKELAARPISLAAEHYGYNYARFSFANYGPYYCQVRKLVLQNVLSSTRLEKVKHVRISEVEISIKELYSESSKVINISQWFEKLTLNIIVKMIAGKRYGSLEKDEEAQCFRRAFAKIMYLAGQFILYDSIPFQIFKYLDFQGHIKTMKQIYKDLDDILQSWVNEHMEKNKKVADDDEEQDCIDAMLSVTKPDDFKAYGYTRDTVIKATVLSMILDGSDTTAVHLTWVMSLLLNNPHVMKHAQEEIDNKVGTEKWVEESDIKDLVYLQAIVKEALRLYPPAPLLVPHEAVEDCTVAGYNIPKGTRLFPNAWKIQRDPRVYSEPDKFMPERFLDKHSNVDARGQHFEFIPFGSGRRSCPGINFATQVAHLTISRLIQGFTYGTPSNLPVDMTEGQGITMPKANPVEVVITPRLNSVLYEL(SEQID NO:1)。
因此,本发明的第一个目的在于提供一种分离的多肽,所述的多肽选自下组:
(a)具有SEQ ID NO:1氨基酸序列的多肽;
(b)将SEQ ID NO:1氨基酸序列经过一个或多个氨基酸残基的取代、缺失或添加而形成的,且具有(a)多肽功能的由(a)衍生的多肽;
(c)与(a)限定的多肽序列有95%以上同源性,优选地98%以上同源性,更优地99%以上同源性,且具有(a)多肽功能的由(a)衍生的多肽;或
(d)序列中含有(a)或(b)或(c)中所述多肽序列的衍生多肽。
为表述方便起见,将氨基酸序列为SEQ ID NO:1的多肽命名为“三分三细胞色素P450酶”或者“三分三P450酶”或者“CYP82M3”或者“AaCYP82M3”。
本发明的第二个目的在于提供编码上述多肽的多核苷酸(或称基因)。上述的多核苷酸选自:
(A)编码上述多肽的多核苷酸;
(B)编码如SEQ ID NO:1所示氨基酸序列的多肽的多核苷酸;
(C)核苷酸序列如SEQ ID NO:2所示的多核苷酸;
(D)核苷酸序列与SEQ ID NO:2所示核苷酸序列的同源性≥95%,优选地≥98%,更优地≥99%的多核苷酸;
(E)与(A)-(D)任一所述的核苷酸序列互补的核苷酸序列。
其中,编码SEQ ID NO:1氨基酸序列的多核苷酸优选为SEQ ID NO:2。
本发明的第三个目的在于提供包含上述基因的载体比如质粒。
本发明的第四个目的在于提供转化了上述载体比如质粒的微生物。
优选地,上述微生物选自大肠杆菌、毕赤酵母、酿酒酵母、解脂耶氏酵母、枯草杆菌。更优选为酿酒酵母。
本发明的第四个目的在于提供上述多肽(比如三分三细胞色素P450酶)、或者其表达微生物在制托品酮中的用途。具体而言,本发明提供了一种制备托品酮的方法,包括如下步骤:以4-(1-甲基-2-吡咯烷基)-3-氧代丁酸为底物原料,在上述多肽(比如三分三P450酶)和一种细胞色素P450还原酶的联合催化下进行分子内缩合反应来制备出托品酮。
在上述制备托品酮的方法中,更优选上述多肽(比如三分三P450酶)与CPR1或CPR2进行组合配对来催化4-(1-甲基-2-吡咯烷基)-3-氧代丁酸的转化反应。
在一种实施方式中,反应体系中还添加有二硫苏糖醇(DTT)。二硫苏糖醇作为还原剂,用于打断二硫键,保持酶中巯基的还原态,保护蛋白的稳定性。
优选地,上述反应体系中还添加有NADPH(还原型辅酶II,还原型烟酰胺腺嘌呤二核苷酸磷酸)。NADPH是一种辅酶,也叫作还原氢,在化学反应中起传递电子的作用。
在一种实施方式中,上述细胞色素P450还原酶优选是三种CPR1-3(或称AaCPR1-3)中的一种,其中CPR1(即AaCPR1)的氨基酸序列为SEQ ID NO:3:
MESTSEKLSAFDFMAAIVKGGNIFDRLNSSLDSGDSSSTALLMENKDLMMILTTSVAVLIGCAVVLMWRRSSTSAKKVVEPPKLVVPKSVIEPEEIDDGKKKITIFFGTQTGTAEGFAKALAEEAKARYDKATFKVIDMDDYAADDEEYEEKLKKETFAFFFLATYGDGEPTDNAARFYKWFVEGKERGDYFKNLQYGVFGLGNRQYEHFNKIAKVVDELLVEQGGQRLVPVGLGDDDQCIEDDITAWRELLWPELDKVLLDGDDATAATPYTAAVLEYRVVIHEKSSFDNDLTTANGHANGHVIVDAQHPCRANVAVRKELHTPASDRSCTHLEFDIPGTGLAYETGDHVGVYCENFIETVEEAERLLNISPDTFFSIHTDKEDGTPLGGSSLPSPFPPCTLRTALTRYADLLSSPKKSALLTLAAFASDPNEADRLRYLASPAGKEEYAQWIIASQRSLLEVMAEFPSAKPSVGVFFASVAPRLQPRFYSISSSPRMAPSRIHVTCALVYDKMPTGRVHKGVCSTWMKNAIPLEESLSCSTAPIFVRQSNFKLPADNKIPIIMIGPGTGLAPFRGFLQERLASKKEGAELGPAVLFFGCRNRQMDYIYQDELDNFLEAGALSELVVAFSREGPNKEYVQHKMSEKAADIWNMISQGGYVYVCGDAKGMARDVHRTLNTIAQNQGSLDSSKAESLVKNLQTTGRYLRDVW(SEQ ID NO:3);
CPR2(即AaCPR2)的氨基酸序列为SEQ ID NO:5:
MESTSEKLSPFDFMAAIFKGGKIFDKLNSSLDSGDSSSSASLAALLMENKDLMMILTTSVAVLIGCAVVLMWRRSSTSAKKVMEPTKLVVPKSVIEPEDINDGKKKITIFFGTQTGTAEGFAKALAEEAKARYDKATFKVIDMDDYAADDEEYEEKLKKETFAFFFLATYGDGEPTDNAARFYKWFVEGKERGDYFKNLQYGVFGLGNRQYEHFNKIAKVVDELLVEQGGQRLVPVGLGDDDQCIEDDITAWRELLWPELDKVLLDGDDATAATPYTAAVLEYRVVIHEKSSFDNDLTTANGHANGHVIVDAQHPCRANVAVRKELHTPASDRSCTHLEFDIPGTGLAYETGDHVGVYCENFIETVEEAERLLNISPDTFFSIHTDKEDGTPLGGSSLPSPFPPCTLRTALTRYADLLSSPKKSALLTLAAFASDPNEADRLRYLASPAGKEEYAQWIIASQRSLLEVMAEFPSAKPSVGVFFASVAPRLQPRFYSISSSPRMAPSRIHVTCALVYDKMPTGRVHKGVCSTWMKNAIPLEESLSCSTAPIFVRQSNFKLPADNKIPIIMIGPGTGLAPFRGFLQERLASKKEGAELGPAVLFFGCRNRQMDYIYQDELDNFLEAGALSELVVAFSREGPNKEYVQHKMSEKAADIWNMISQGGYVYVCGDAKGMARDVHRTLHIIAHDQGSLDNSKAESLVKNLQTTGRYLRDVW(SEQ ID NO:5);
CPR3(即AaCPR3)的氨基酸序列为SEQ ID NO:7:
MESSSELVRSVESAIGVSLGSDTVLVLLTTSFAVIVGLIVLFFKRSSDRSKEVKPVVFPKSLQVEPEEETEPEPGKVKVTVFFGTQTGTAEGFAKALSEEIKARYEKAVVKVVDMDDYAADDELYEEKLKKETVAFFMVATYGDGEPTDNAARFYKWFTEGQERGAWLQHLTYGVFGLGNRQYEHFNKIGKVIDEQLSEQGAKRLVPVGLGDDDQCIEDDFAAWREQLWPELDQILKDEDDANSAATPYTAAIPEYRLVIHDTTMSLEDKHANMANGNTTYDIHHPCKVNVAIQRELHTPESDRSCLHLEFDISGTGISYETGDHVGVYAENSEETVEEAARLLGQSLDLVFSIHTDKEDGTSVGGSLPPPFPGPCTLRAALARYTDLLNPPRKATLVALAAHAAEPSEAEKLKFLASPQGKDEYSQWIVASQRSLVEVMAEFPSAKPPLGVFFAAVAPRLQPRYYSISSSPRFAPARVHVTCALVYGPTPTGRIHKGVCSTWMKNAVPLKKSHNCSSAPIFIRPSNFKLPADPSIPIVMVGPGTGLAPFRGFLQERAALKEDGAQLGPALLFFGCRNRRTDFIYEEELQSFVDQGVISELIIAFSREGPQKEYVQHKMMEKASQVWSSISQEGYLYVCGDAKGMARDVHRTLHTIVQEQEKADSTKAEAIVKKLQMDGRYLRDVW(SEQ ID NO:7)。
本发明还提供了编码上述三分三细胞色素P450还原酶CPR1-3的基因。
在一种优选的实施方式中,编码上述CPR1的基因是SEQ ID NO:4;编码上述CPR2的基因是SEQ ID NO:6;编码上述CPR3的基因是SEQ ID NO:8。
本发明还提供了用于表达上述三分三细胞色素P450还原酶CPR1-3的微生物。
优选地,上述微生物选自大肠杆菌和酿酒酵母。更优选为酿酒酵母。
在一种优选的实施方式中,上述多肽(比如三分三P450酶)和一种细胞色素P450还原酶CPR1-3在同一个微生物中共表达。
可选地,上述多肽(比如三分三P450酶)和一种细胞色素P450还原酶CPR1-3也可以在不同的微生物中分别表达。
相应地,就催化体系而言,上述多肽(比如三分三P450酶)和一种细胞色素P450还原酶CPR1-3的组合可以是酶+酶的形式、酶+菌体的形式、或者菌体+菌体的形式。
上述的酶催化反应的反应温度优选为25-35℃、优选30℃,并且在pH6.5-7.5、优选pH6.8的反应体系中进行缩合反应。优选反应体系为缓冲溶液体系。
当上述微生物共表达上述多肽(比如三分三P450酶)和一种细胞色素P450还原酶CPR1-3时,优选将多肽(比如三分三P450酶)基因和CPR1-3基因构建在不同的质粒上,转化入微生物,构建成同时表达两类酶的基因工程菌。
当用于共表达上述多肽(比如三分三P450酶)和一种CPR1-3的微生物是酿酒酵母时,可采用酵母菌By4742作为宿主菌。这种情况下,可以将上述多肽(比如三分三P450酶)基因克隆于质粒pESC-URA上,并将CPR1-3基因克隆于质粒pESC-HIS上。
当上述微生物是酿酒酵母时,优选培养基是YPD培养基、或者任何适合于酿酒酵母发酵的培养基。
本发明的双酶联合催化体系可以“一锅法”催化4-(1-甲基-2-吡咯烷基)-3-氧代丁酸转化为托品酮,完善了三分三莨菪生物碱的生物合成途径,具有工业化开发和应用前景。
附图说明
图1显示了AaCYP82M3和AaCPR1-3基因片段的琼脂糖凝胶电泳照片。
图2显示了的液质联用仪(LC/MS)检测两类酶AaCYP82M3和AaCPR1-3催化反应产物托品酮的质谱图。
图3显示了托品酮的离子碎片结果。其中,A是产物托品酮标品的二级碎片;B是AaCYP82M3-AaCPR1组合催化的产物离子碎片结果;C是AaCYP82M3-AaCPR2组合催化的产物离子碎片结果;D是AaCYP82M3-AaCPR3组合催化的产物离子碎片结果。
具体实施方式
以下结合具体实施例对本发明做进一步详细说明。应理解,以下实施例仅用于说明本发明而非用于限定本发明的范围。
本文中涉及到多种物质的添加量、含量及浓度,其中所述的百分含量,除特别说明外,皆指质量百分含量。
本文的实施例中,如果对于操作温度没有做出具体说明,则该温度通常指室温。
本发明通过两种酶组成的联合催化体系“一锅法”催化4-(1-甲基-2-吡咯烷基)-3-氧代丁酸进行反应,合成得到托品酮。其中术语“联合催化体系”是指AaCYP82M3与AaCPR1-3的组合,包括但不限于酶表达菌株的组合。
需说明的是,本文中AaCPR1-3表示三种细胞色素P450还原酶AaCPR(或称CPR)中的一种即AaCPR1或AaCPR2或AaCPR3,并不是指它们中两种或三种的混合物。
当作为生物催化剂用于生产托品酮时,本发明的酶AaCYP82M3和AaCPR1-3可以呈现酶的形式或者菌体的形式。所述酶的形式包括游离酶、固定化酶,包括纯化酶、粗酶、发酵液、载体固定的酶等。而且这些酶的分离纯化、包括固定化酶制备技术也是本领域技术人员所熟知的。所述菌体的形式包括存活菌体和死亡菌体,包括冻融的菌体、固定化的菌体。
在本文中,有时为了描述简便,会将蛋白比如CYP82M3蛋白质名称与其编码基因(DNA)名称混用,本领域技术人员应能理解它们在不同描述场合表示不同的物质。例如,对于CYP82M3(基因),用于描述单氧酶功能或类别时,指的是蛋白质;在作为一种基因描述时,指的是编码该P450酶的基因,以此类推,这是本领域技术人员容易理解的。
本发明中使用的酶AaCYP82M3和AaCPR1-3序列明确,因此本领域技术人员能够容易地获得其编码基因、包含这些基因的表达盒和质粒、以及包含该质粒的转化体。这些基因、表达盒、质粒、转化体可以通过本领域技术人员所熟知的基因工程构建方式获得。
实施例
材料和方法
实施例中的全基因合成、引物合成及测序皆由上海桑尼生物科技有限公司完成。
实施例中的分子生物学实验包括质粒构建、酶切、连接、感受态细胞制备、转化、培养基配制等等,主要参照《分子克隆实验指南》(第三版),J.萨姆布鲁克,D.W.拉塞尔(美)编著,黄培堂等译,科学出版社,北京,2002)进行。必要时可以通过简单试验确定具体实验条件。
PCR扩增实验根据质粒或DNA模板供应商提供的反应条件或试剂盒说明书进行。必要时可以通过简单试验予以调整。
LB培养基:10g/L胰蛋白胨、5g/L酵母提取物、10g/L氯化钠,pH 7.0。
YPD培养基:10.0g/L酵母提取物,20.0g/L蛋白胨,20.0g/L葡萄糖。
YPAD培养基:10.0g/L酵母提取物、20.0g/L蛋白胨、20.0g/L D-葡萄糖、0.4g/L硫酸腺嘌呤。
LC-MS测定条件:用等体积的甲醇150μL去除蛋白,蜗旋震荡,12000rpm离心5min,上清浓缩,后用100μL 50%MeOH溶解,过0.22μm滤膜后进行质谱分析。仪器型号为液相-质谱联用仪为Agilent 1290 UHPLC-Agilent 6545 Q-TOF ESI质谱。采用色谱柱Agilent C18(4.6×150mm,3.5μm);柱温:30℃;流动相A:0.1%甲酸,有机相B:乙腈;流速:0.25mL/min;进样量:2μL。
实施例1三分三细胞色素P450和细胞色素P450还原酶基因的克隆
1.1总RNA的提取与检测
打开超净台和紫外灯,用乙醇烧研钵、钥匙、剪刀。剪下三分三毛状根100mg,液氮中将组织研磨成粉末,分装至Ep管中,液氮挥发后加1ml Trizol-x-100,立即用力震荡或用移液器吹吸5-8次(没有块状物为止),室温静置5min;用等体积氯仿抽提2次,7500g离心15min;上清液加入等体积提前预冷的异丙醇,混匀后室温放置30min,4℃、10000g离心10min;沉淀加入1ml 75%乙醇进行清洗,4℃、10000g离心10min;沉淀室温干燥10min后溶于25μL DEPC处理的水中,用1.0%琼脂糖凝胶电泳检测RNA的完整性,用Eppendorf核酸定量仪测定A260、A280比值和浓度。置于-80℃冰箱备用。
1.2反转录合成cDNA
采用TakaRa公司提供的PrimeScript反转录试剂盒,合成三分三mRNA第一条互补链cDNA。
1.3三分三细胞色素P450(AaCYP82M3)和细胞色素P450还原酶(AaCPR1-3)基因的克隆
从NCBI中搜索三分三基因相关的核苷酸序列和EST序列,通过比对分析,利用vector NTI软件设计4对扩增引物,如表1所示。
表1扩增所需引物
Figure BDA0002027643590000081
Figure BDA0002027643590000091
其中,F是正向引物;R是反向引物。
以三分三的cDNA为模板,按照以下体系[5×phusion buffer 4.0μL,dNTP(2.5mM)1.6μL,引物(2μM)各2μL,DMSO 0.6μL,cDNA 0.5μL,Phusion DNA聚合酶0.2μL,补加ddH2O至终体积20.0μL]扩增AaPYKS基因,反应程序:98℃预变性30s,98℃变性10s,56℃退火30s,72℃延伸1min 30s,30个循环,72℃终延伸5min,16℃保存。扩增的基因片段的1%琼脂糖凝胶电泳检测结果如图1所示。利用Axygen公司的Agarose Gel Fragment Recovery KitVer.2.0纯化PCR产物,然后克隆至pMD19-T载体,筛选阳性克隆提取的质粒送桑尼公司测序,获得细胞色素P450(AaCYP82M3)及细胞色素P450还原酶(AaCPR1-3)相关基因序列(SEQID NO:2、SEQ ID NO:4、SEQ ID NO:6、SEQ ID NO:8)。
实施例2真核表达载体的构建
2.1克隆AaCYP82M3以及AaCPR1-3基因:使用Axygen的质粒抽提试剂盒抽提测序正确的T载体,以T载体中的AaCYP82M3以及AaCPR1-3基因为模板,利用表1引物,进行PCR扩增,按照以下体系〔5×phusion缓冲液4.0μL,dNTP(2.5mM)1.6μL,引物(2μM)各2μL,DMSO 0.6μL,cDNA 0.5μL,Phusion DNA聚合酶0.2μL,补加ddH2O至终体积20.0μL〕扩增基因,反应程序:98℃预变性30s,98℃变性10s,55℃退火30s,72℃延伸2min,30个循环,72℃终延伸5min,使用Axygen的胶回收试剂进行回收,得到相应的片段。
2.2基因双酶切:将AaCYP82M3的PCR产物,经限制性内切酶BamHI和KpnI于37℃酶切2h;将AaCPR1的PCR产物,经限制性内切酶BamHI和XhoI于37℃酶切2h;将AaCPR2的PCR产物,经限制性内切酶BamHI和XhoI于37℃酶切2h;将AaCPR3的PCR产物,经限制性内切酶BamHI和XhoI于37℃酶切2h。分别将上述酶切产物进行胶回收。
2.3表达质粒双酶切:pESC-URA经限制性内切酶BamHI和KpnI于37℃酶切2h;pESC-HIS经限制性内切酶BamHI和XhoI于37℃酶切2h。
2.4连接:利用T4DNA连接酶,将酶切后的质粒及基因于20℃连接2h,转化DH5α感受态细胞(购买自南京诺唯赞生物科技有限公司的商品化感受态细胞),涂布氨苄霉素LB平板,过夜培养。
2.5菌落PCR验证:利用表1引物进行PCR验证转化子,PCR体系如下([5×phusionbuffer 4.0μL,dNTP(2.5mM)1.6μL,引物(2μM)各2μL,DMSO 0.6μL,cDNA 0.5μL,PhusionDNA聚合酶0.2μL,补加ddH2O至终体积20.0μL]扩增基因,反应程序:98℃预变性30s,98℃变性10s,56℃退火30s,72℃延伸1min 30s,30个循环,72℃终延伸5min,)。阳性菌接入LB液体试管,使用Axygen的质粒抽提试剂盒抽提质粒进行测序,从而得到正确的表达质粒。
实施例3 AaCYP82M3和AaCPR1-3表达菌株的构建
酿酒酵母菌By4742在YPD板上划线,30℃培养2天;挑酵母菌单菌落接至5mL YPAD液体培养基中,30℃,200rpm培养过夜;将酵母菌液稀释10倍,测OD600,此时OD600应为0.4-0.5(表示生长良好)。按比例1:20到1:25转接到2*YPAD(生长速度快),50mL培养,使起始OD600小于等于0.2;在30℃,200rpm培养至OD600为0.5,约4-5个小时;-20℃冻存的载体DNA(鱼精DNA)100℃变性5分钟后,立刻插入冰里(保持单链)。室温下1,000g离心5分钟收集菌体,用1/2体积无菌水重悬(如50mL菌液用25mL无菌水重悬)离心;1/2体积无菌水再洗一次,1,000g离心5分钟离心收集菌体。用2mL TE/LiAc重悬后,10*200μL每管分装备用;在1.5mLEP管中加入1-5μg实施例2中构建得到的质粒DNA,200μg鲑鱼精DNA(变性的,2mg/ml)加入200μL感受态细胞,轻弹混匀,加入600μL PEG/LiAC,轻弹混匀;30℃,200rpm,30min复苏,加入70μL DMSO温和混匀。42℃热激15min,每5-10min,间歇轻弹混匀,冰上2min,1000g离心3min。弃上清,用液体200μL H2O培养基重悬,涂板在相应的缺陷性培养基(即,不含组氨酸和尿嘧啶的SD培养基)中进行筛选,筛选出阳性克隆株。
实施例4酿酒酵母的微粒体的提取
从缺陷性培养基上挑取单菌落,接种到2mL SD液体培养基(6.7g/L无氨基的酵母氮源,20g/L葡萄糖,1.3g氨基酸粉末,缺陷性培养基中不含组氨酸和尿嘧啶)中培养过夜,按比例1:50稀释转接到200mLSD培养基中,30℃,200rpm培养至OD600约为0.6。离心后收集细胞,转接到200mL SG液体培养基(6.7g/L无氨基的酵母氮源,20g/L半乳糖,1.3g氨基酸粉末,缺陷性培养基中不含组氨酸和尿嘧啶)中培养过夜,继续培养36小时,收集细胞。细胞用1/10体积的磷酸溶液进行重悬,压榨破碎,于4℃,15000g离心20min,取上清后利用超速离心机4℃,100,000g离心60min,取沉淀,利用磷酸溶液进行重悬,得到包含AaCYP82M3和AaCPR1-3蛋白质的微粒体,分装后放置-80℃,待检测活性。
实施例5酿酒酵母微粒体的活性检测
在磷酸缓冲液(10mM,pH 7.0)中配制酶反应体系,取500μg粗酶液(即包含AaCYP82M3和AaCPR1-3的酿酒酵母微粒体),加入1mM DTT、1mM NADPH,0.2mM 4-(1-甲基-2-吡咯烷基)-3-氧代丁酸,至体积150μL。于30℃反应过夜后,用等体积的甲醇沉淀蛋白,12000g离心5min,上清过0.22μm滤膜后利用高分辨质谱进行检测。
检测结果参见图2和图3,图2显示了AaCYP82M3和AaCPR1-3催化4-(1-甲基-2-吡咯烷基)-3-氧代丁酸反应生成目标产物托品酮。图3的离子碎片验证了产物是目标化合物托品酮。
实施例5的结果表明,本发明的三分三细胞色素P450(AaCYP82M3)和细胞色素P450还原酶(AaCPR1-3)能够有效地催化4-(1-甲基-2-吡咯烷基)-3-氧代丁酸反应并转化成托品酮。本领域技术人员显然容易理解,与化学合成法相比,本发明的生物合成法具有绿色环保的天然优势,因而具有工业化开发和应用前景。
还需说明的是,本说明书中对先前公开的文献的列举和论述不应视为承认该文献是现有技术或者是公知常识。
序列表
<110> 中国科学院上海生命科学研究院
<120> 三分三P450酶及其在制备托品酮中的应用
<130> SHPI1910089
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 519
<212> PRT
<213> Anisodus acutangulus
<400> 1
Met Tyr Asp Asn Phe Pro Phe Tyr Asp Leu Gln Ile Ile Leu Gly Val
1 5 10 15
Leu Leu Thr Phe Val Val Ser Ile Ile Leu Trp Thr Arg Asn Trp Lys
20 25 30
Ser Pro Lys Leu Pro Pro Lys Ile Pro Gly Ser Trp Pro Ile Ile Gly
35 40 45
His Leu Arg Gly Phe Gly Asp Gly Glu Asn Val Pro Leu Ala Arg Thr
50 55 60
Phe Gly Lys Leu Ser Asp Gln Tyr Gly Pro Ile Phe Thr Ile Lys Leu
65 70 75 80
Gly Met Phe Arg Tyr Cys Val Ile Asn Asn Trp Glu Ala Ala Lys Asp
85 90 95
Cys Phe Thr Ile His Asp Lys Glu Leu Ala Ala Arg Pro Ile Ser Leu
100 105 110
Ala Ala Glu His Tyr Gly Tyr Asn Tyr Ala Arg Phe Ser Phe Ala Asn
115 120 125
Tyr Gly Pro Tyr Tyr Cys Gln Val Arg Lys Leu Val Leu Gln Asn Val
130 135 140
Leu Ser Ser Thr Arg Leu Glu Lys Val Lys His Val Arg Ile Ser Glu
145 150 155 160
Val Glu Ile Ser Ile Lys Glu Leu Tyr Ser Glu Ser Ser Lys Val Ile
165 170 175
Asn Ile Ser Gln Trp Phe Glu Lys Leu Thr Leu Asn Ile Ile Val Lys
180 185 190
Met Ile Ala Gly Lys Arg Tyr Gly Ser Leu Glu Lys Asp Glu Glu Ala
195 200 205
Gln Cys Phe Arg Arg Ala Phe Ala Lys Ile Met Tyr Leu Ala Gly Gln
210 215 220
Phe Ile Leu Tyr Asp Ser Ile Pro Phe Gln Ile Phe Lys Tyr Leu Asp
225 230 235 240
Phe Gln Gly His Ile Lys Thr Met Lys Gln Ile Tyr Lys Asp Leu Asp
245 250 255
Asp Ile Leu Gln Ser Trp Val Asn Glu His Met Glu Lys Asn Lys Lys
260 265 270
Val Ala Asp Asp Asp Glu Glu Gln Asp Cys Ile Asp Ala Met Leu Ser
275 280 285
Val Thr Lys Pro Asp Asp Phe Lys Ala Tyr Gly Tyr Thr Arg Asp Thr
290 295 300
Val Ile Lys Ala Thr Val Leu Ser Met Ile Leu Asp Gly Ser Asp Thr
305 310 315 320
Thr Ala Val His Leu Thr Trp Val Met Ser Leu Leu Leu Asn Asn Pro
325 330 335
His Val Met Lys His Ala Gln Glu Glu Ile Asp Asn Lys Val Gly Thr
340 345 350
Glu Lys Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr Leu Gln
355 360 365
Ala Ile Val Lys Glu Ala Leu Arg Leu Tyr Pro Pro Ala Pro Leu Leu
370 375 380
Val Pro His Glu Ala Val Glu Asp Cys Thr Val Ala Gly Tyr Asn Ile
385 390 395 400
Pro Lys Gly Thr Arg Leu Phe Pro Asn Ala Trp Lys Ile Gln Arg Asp
405 410 415
Pro Arg Val Tyr Ser Glu Pro Asp Lys Phe Met Pro Glu Arg Phe Leu
420 425 430
Asp Lys His Ser Asn Val Asp Ala Arg Gly Gln His Phe Glu Phe Ile
435 440 445
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Ile Asn Phe Ala Thr
450 455 460
Gln Val Ala His Leu Thr Ile Ser Arg Leu Ile Gln Gly Phe Thr Tyr
465 470 475 480
Gly Thr Pro Ser Asn Leu Pro Val Asp Met Thr Glu Gly Gln Gly Ile
485 490 495
Thr Met Pro Lys Ala Asn Pro Val Glu Val Val Ile Thr Pro Arg Leu
500 505 510
Asn Ser Val Leu Tyr Glu Leu
515
<210> 2
<211> 1560
<212> DNA
<213> Anisodus acutangulus
<400> 2
atgtatgata attttccctt ctatgatctg caaattatac ttggagtcct tctaactttt 60
gttgtatcaa tcattctatg gacaagaaat tggaaaagtc caaaactacc ccccaaaatc 120
cctggatcat ggccaattat aggccatctc cgtggttttg gcgatggcga aaacgtccct 180
ctagcacgaa cattcggaaa attatccgat caatatggtc caattttcac tattaagctt 240
ggcatgtttc gttattgtgt gattaataat tgggaagcag ctaaagattg cttcacaatt 300
catgataaag aactcgctgc tagaccaatt agtctagcag ctgaacatta tggctataat 360
tacgcaagat tttcttttgc taattatggt ccatattatt gccaagtacg aaaactcgtg 420
ttacaaaatg ttctttctag tactagactt gaaaaagtca aacatgtccg aatttccgag 480
gtggaaatta gcatcaaaga attatatagt gaaagttcca aagtgattaa tattagtcaa 540
tggttcgaaa aattgacttt gaatataatt gtgaagatga ttgctgggaa aagatatgga 600
tctttggaga aagatgaaga ggcacaatgt tttagaaggg cttttgctaa gataatgtat 660
cttgctgggc aattcatttt atatgactct attccgttcc aaattttcaa atatttggat 720
tttcaagggc atattaagac catgaagcaa atttacaagg acttggatga tattcttcaa 780
agttgggtta atgaacatat ggagaaaaat aagaaggttg cagatgatga tgaagaacaa 840
gattgtatag atgcaatgct ttcagtgaca aagcctgatg atttcaaagc ctatggttat 900
acacgagata cagttatcaa ggcaactgta ttgagcatga tattggatgg ttcagataca 960
actgcagttc acctaacatg ggtcatgtcc ctattattga acaatcctca cgtcatgaaa 1020
catgcccaag aagaaataga caacaaagtt ggtacagaaa aatgggttga agaatccgat 1080
atcaaagatc ttgtctatct ccaagctatt gttaaagaag cgttgcgctt atatccacca 1140
gcacctttgt tagtcccaca cgaagctgtg gaagattgta ccgtggcagg gtacaacatc 1200
ccaaagggta ctcgtttgtt cccgaacgca tggaagatac aacgagaccc tcgggtttat 1260
tcagagcccg ataagttcat gccagagaga ttcttagaca aacattcgaa tgtggatgct 1320
cgtggtcagc attttgagtt catcccgttt ggttctggaa gacggtcttg tcctggaatt 1380
aattttgcaa cgcaagtggc gcatctcaca attagtcgat taattcaagg atttacctat 1440
ggtacaccat caaatttgcc agttgatatg actgaaggtc aaggtattac tatgcctaaa 1500
gcaaatcctg tggaagttgt aatcaccccg cgtttgaatt ctgtgcttta tgaactttga 1560
<210> 3
<211> 711
<212> PRT
<213> Anisodus acutangulus
<400> 3
Met Glu Ser Thr Ser Glu Lys Leu Ser Ala Phe Asp Phe Met Ala Ala
1 5 10 15
Ile Val Lys Gly Gly Asn Ile Phe Asp Arg Leu Asn Ser Ser Leu Asp
20 25 30
Ser Gly Asp Ser Ser Ser Thr Ala Leu Leu Met Glu Asn Lys Asp Leu
35 40 45
Met Met Ile Leu Thr Thr Ser Val Ala Val Leu Ile Gly Cys Ala Val
50 55 60
Val Leu Met Trp Arg Arg Ser Ser Thr Ser Ala Lys Lys Val Val Glu
65 70 75 80
Pro Pro Lys Leu Val Val Pro Lys Ser Val Ile Glu Pro Glu Glu Ile
85 90 95
Asp Asp Gly Lys Lys Lys Ile Thr Ile Phe Phe Gly Thr Gln Thr Gly
100 105 110
Thr Ala Glu Gly Phe Ala Lys Ala Leu Ala Glu Glu Ala Lys Ala Arg
115 120 125
Tyr Asp Lys Ala Thr Phe Lys Val Ile Asp Met Asp Asp Tyr Ala Ala
130 135 140
Asp Asp Glu Glu Tyr Glu Glu Lys Leu Lys Lys Glu Thr Phe Ala Phe
145 150 155 160
Phe Phe Leu Ala Thr Tyr Gly Asp Gly Glu Pro Thr Asp Asn Ala Ala
165 170 175
Arg Phe Tyr Lys Trp Phe Val Glu Gly Lys Glu Arg Gly Asp Tyr Phe
180 185 190
Lys Asn Leu Gln Tyr Gly Val Phe Gly Leu Gly Asn Arg Gln Tyr Glu
195 200 205
His Phe Asn Lys Ile Ala Lys Val Val Asp Glu Leu Leu Val Glu Gln
210 215 220
Gly Gly Gln Arg Leu Val Pro Val Gly Leu Gly Asp Asp Asp Gln Cys
225 230 235 240
Ile Glu Asp Asp Ile Thr Ala Trp Arg Glu Leu Leu Trp Pro Glu Leu
245 250 255
Asp Lys Val Leu Leu Asp Gly Asp Asp Ala Thr Ala Ala Thr Pro Tyr
260 265 270
Thr Ala Ala Val Leu Glu Tyr Arg Val Val Ile His Glu Lys Ser Ser
275 280 285
Phe Asp Asn Asp Leu Thr Thr Ala Asn Gly His Ala Asn Gly His Val
290 295 300
Ile Val Asp Ala Gln His Pro Cys Arg Ala Asn Val Ala Val Arg Lys
305 310 315 320
Glu Leu His Thr Pro Ala Ser Asp Arg Ser Cys Thr His Leu Glu Phe
325 330 335
Asp Ile Pro Gly Thr Gly Leu Ala Tyr Glu Thr Gly Asp His Val Gly
340 345 350
Val Tyr Cys Glu Asn Phe Ile Glu Thr Val Glu Glu Ala Glu Arg Leu
355 360 365
Leu Asn Ile Ser Pro Asp Thr Phe Phe Ser Ile His Thr Asp Lys Glu
370 375 380
Asp Gly Thr Pro Leu Gly Gly Ser Ser Leu Pro Ser Pro Phe Pro Pro
385 390 395 400
Cys Thr Leu Arg Thr Ala Leu Thr Arg Tyr Ala Asp Leu Leu Ser Ser
405 410 415
Pro Lys Lys Ser Ala Leu Leu Thr Leu Ala Ala Phe Ala Ser Asp Pro
420 425 430
Asn Glu Ala Asp Arg Leu Arg Tyr Leu Ala Ser Pro Ala Gly Lys Glu
435 440 445
Glu Tyr Ala Gln Trp Ile Ile Ala Ser Gln Arg Ser Leu Leu Glu Val
450 455 460
Met Ala Glu Phe Pro Ser Ala Lys Pro Ser Val Gly Val Phe Phe Ala
465 470 475 480
Ser Val Ala Pro Arg Leu Gln Pro Arg Phe Tyr Ser Ile Ser Ser Ser
485 490 495
Pro Arg Met Ala Pro Ser Arg Ile His Val Thr Cys Ala Leu Val Tyr
500 505 510
Asp Lys Met Pro Thr Gly Arg Val His Lys Gly Val Cys Ser Thr Trp
515 520 525
Met Lys Asn Ala Ile Pro Leu Glu Glu Ser Leu Ser Cys Ser Thr Ala
530 535 540
Pro Ile Phe Val Arg Gln Ser Asn Phe Lys Leu Pro Ala Asp Asn Lys
545 550 555 560
Ile Pro Ile Ile Met Ile Gly Pro Gly Thr Gly Leu Ala Pro Phe Arg
565 570 575
Gly Phe Leu Gln Glu Arg Leu Ala Ser Lys Lys Glu Gly Ala Glu Leu
580 585 590
Gly Pro Ala Val Leu Phe Phe Gly Cys Arg Asn Arg Gln Met Asp Tyr
595 600 605
Ile Tyr Gln Asp Glu Leu Asp Asn Phe Leu Glu Ala Gly Ala Leu Ser
610 615 620
Glu Leu Val Val Ala Phe Ser Arg Glu Gly Pro Asn Lys Glu Tyr Val
625 630 635 640
Gln His Lys Met Ser Glu Lys Ala Ala Asp Ile Trp Asn Met Ile Ser
645 650 655
Gln Gly Gly Tyr Val Tyr Val Cys Gly Asp Ala Lys Gly Met Ala Arg
660 665 670
Asp Val His Arg Thr Leu Asn Thr Ile Ala Gln Asn Gln Gly Ser Leu
675 680 685
Asp Ser Ser Lys Ala Glu Ser Leu Val Lys Asn Leu Gln Thr Thr Gly
690 695 700
Arg Tyr Leu Arg Asp Val Trp
705 710
<210> 4
<211> 2136
<212> DNA
<213> Anisodus acutangulus
<400> 4
atggagtcga catcagaaaa actttctgct tttgatttta tggcagcgat cgttaaggga 60
ggaaatatat ttgatagact gaactcgtca ttagattctg gtgactcaag ttcgacagct 120
ttgttgatgg agaacaaaga tttgatgatg atattgacaa cctcggttgc tgttttaatt 180
ggatgtgcag ttgtcttgat gtggcggcgc tcctcgacat ctgctaagaa ggttgttgaa 240
ccaccgaaat tggtggttcc taagtcggtt atagaacctg aagagattga tgatggcaag 300
aagaaaatta ccatcttttt tggaacccag actggtacag cagaaggctt cgcaaaggca 360
cttgctgagg aagccaaggc cagatatgac aaggctacct ttaaagtgat tgatatggat 420
gattatgcgg ctgatgatga agagtatgaa gagaaattga agaaagaaac attcgcattc 480
tttttcttgg cgacatatgg agatggtgaa ccaactgata acgctgccag attctataag 540
tggtttgtag agggaaaaga gaggggtgac tacttcaaga atcttcagta tggagtattt 600
gggcttggta acagacaata cgagcatttc aacaagattg ctaaagttgt ggatgaactt 660
ctggttgagc aaggtggaca gaggcttgtt ccagtgggtc ttggagatga tgaccaatgc 720
attgaagatg atattactgc atggcgtgaa ttactgtggc ctgaattgga taaggtgctt 780
cttgatgggg atgatgcaac tgctgcaact ccatatactg ctgcagtttt ggaatatagg 840
gttgttatcc atgaaaagtc cagctttgat aatgacttga ctaccgcaaa tggtcatgca 900
aatggacatg tcattgttga tgctcaacat ccttgcagag ctaatgttgc tgttaggaag 960
gaacttcaca ctcctgcttc tgatcgttct tgcactcatc tggagtttga cattcctggc 1020
actggacttg cgtatgaaac tggtgatcat gttggtgtgt actgtgaaaa ttttattgaa 1080
accgtggagg aagctgaaag gttacttaac atatcgccag acactttctt ttccattcac 1140
actgataaag aggatggcac accacttggt ggaagctcat tgccatctcc cttccctcct 1200
tgcactttga gaacggcatt gactcggtat gctgatcttt tgagttctcc taaaaagtct 1260
gctttactta ctttagcggc atttgcttct gatccaaatg aagctgatcg attacgatat 1320
cttgcatcac ccgctggaaa ggaagaatat gctcagtgga taattgcaag tcagagaagc 1380
cttcttgaag tcatggctga atttccttca gccaagcctt cagtcggtgt tttctttgct 1440
tctgttgctc ctcgcctaca accgagattc tactctatct catcatctcc taggatggcg 1500
ccatctagga ttcatgtcac ttgtgcactg gtttacgaca aaatgccaac tggacgagtt 1560
cacaagggtg tctgctcaac atggatgaag aacgctattc ctctagaaga aagcctttcc 1620
tgcagtacgg cacctatttt tgttcggcaa tcaaacttta aacttccagc tgataacaag 1680
attccaatca taatgattgg ccctggtact gggttggcac cattcagggg tttcctccag 1740
gaaagattag cttcgaagaa ggaaggagcc gagcttggtc ctgcagtgtt attttttgga 1800
tgcaggaacc gccaaatgga ctacatctat caagatgagt tagacaattt cctcgaggct 1860
ggtgcacttt ctgagctagt tgttgctttc tcacgtgaag gacctaacaa agaatacgtg 1920
caacataaaa tgtcagagaa ggctgcggac atctggaaca tgatttctca gggaggatat 1980
gtatatgtat gcggtgatgc taaaggcatg gctagggatg tccatcggac tcttaacact 2040
attgcgcaga atcagggatc acttgacagc tccaaggctg agagcttggt gaagaacttg 2100
caaacgactg gaagatatct gcgtgatgtg tggtga 2136
<210> 5
<211> 715
<212> PRT
<213> Anisodus acutangulus
<400> 5
Met Glu Ser Thr Ser Glu Lys Leu Ser Pro Phe Asp Phe Met Ala Ala
1 5 10 15
Ile Phe Lys Gly Gly Lys Ile Phe Asp Lys Leu Asn Ser Ser Leu Asp
20 25 30
Ser Gly Asp Ser Ser Ser Ser Ala Ser Leu Ala Ala Leu Leu Met Glu
35 40 45
Asn Lys Asp Leu Met Met Ile Leu Thr Thr Ser Val Ala Val Leu Ile
50 55 60
Gly Cys Ala Val Val Leu Met Trp Arg Arg Ser Ser Thr Ser Ala Lys
65 70 75 80
Lys Val Met Glu Pro Thr Lys Leu Val Val Pro Lys Ser Val Ile Glu
85 90 95
Pro Glu Asp Ile Asn Asp Gly Lys Lys Lys Ile Thr Ile Phe Phe Gly
100 105 110
Thr Gln Thr Gly Thr Ala Glu Gly Phe Ala Lys Ala Leu Ala Glu Glu
115 120 125
Ala Lys Ala Arg Tyr Asp Lys Ala Thr Phe Lys Val Ile Asp Met Asp
130 135 140
Asp Tyr Ala Ala Asp Asp Glu Glu Tyr Glu Glu Lys Leu Lys Lys Glu
145 150 155 160
Thr Phe Ala Phe Phe Phe Leu Ala Thr Tyr Gly Asp Gly Glu Pro Thr
165 170 175
Asp Asn Ala Ala Arg Phe Tyr Lys Trp Phe Val Glu Gly Lys Glu Arg
180 185 190
Gly Asp Tyr Phe Lys Asn Leu Gln Tyr Gly Val Phe Gly Leu Gly Asn
195 200 205
Arg Gln Tyr Glu His Phe Asn Lys Ile Ala Lys Val Val Asp Glu Leu
210 215 220
Leu Val Glu Gln Gly Gly Gln Arg Leu Val Pro Val Gly Leu Gly Asp
225 230 235 240
Asp Asp Gln Cys Ile Glu Asp Asp Ile Thr Ala Trp Arg Glu Leu Leu
245 250 255
Trp Pro Glu Leu Asp Lys Val Leu Leu Asp Gly Asp Asp Ala Thr Ala
260 265 270
Ala Thr Pro Tyr Thr Ala Ala Val Leu Glu Tyr Arg Val Val Ile His
275 280 285
Glu Lys Ser Ser Phe Asp Asn Asp Leu Thr Thr Ala Asn Gly His Ala
290 295 300
Asn Gly His Val Ile Val Asp Ala Gln His Pro Cys Arg Ala Asn Val
305 310 315 320
Ala Val Arg Lys Glu Leu His Thr Pro Ala Ser Asp Arg Ser Cys Thr
325 330 335
His Leu Glu Phe Asp Ile Pro Gly Thr Gly Leu Ala Tyr Glu Thr Gly
340 345 350
Asp His Val Gly Val Tyr Cys Glu Asn Phe Ile Glu Thr Val Glu Glu
355 360 365
Ala Glu Arg Leu Leu Asn Ile Ser Pro Asp Thr Phe Phe Ser Ile His
370 375 380
Thr Asp Lys Glu Asp Gly Thr Pro Leu Gly Gly Ser Ser Leu Pro Ser
385 390 395 400
Pro Phe Pro Pro Cys Thr Leu Arg Thr Ala Leu Thr Arg Tyr Ala Asp
405 410 415
Leu Leu Ser Ser Pro Lys Lys Ser Ala Leu Leu Thr Leu Ala Ala Phe
420 425 430
Ala Ser Asp Pro Asn Glu Ala Asp Arg Leu Arg Tyr Leu Ala Ser Pro
435 440 445
Ala Gly Lys Glu Glu Tyr Ala Gln Trp Ile Ile Ala Ser Gln Arg Ser
450 455 460
Leu Leu Glu Val Met Ala Glu Phe Pro Ser Ala Lys Pro Ser Val Gly
465 470 475 480
Val Phe Phe Ala Ser Val Ala Pro Arg Leu Gln Pro Arg Phe Tyr Ser
485 490 495
Ile Ser Ser Ser Pro Arg Met Ala Pro Ser Arg Ile His Val Thr Cys
500 505 510
Ala Leu Val Tyr Asp Lys Met Pro Thr Gly Arg Val His Lys Gly Val
515 520 525
Cys Ser Thr Trp Met Lys Asn Ala Ile Pro Leu Glu Glu Ser Leu Ser
530 535 540
Cys Ser Thr Ala Pro Ile Phe Val Arg Gln Ser Asn Phe Lys Leu Pro
545 550 555 560
Ala Asp Asn Lys Ile Pro Ile Ile Met Ile Gly Pro Gly Thr Gly Leu
565 570 575
Ala Pro Phe Arg Gly Phe Leu Gln Glu Arg Leu Ala Ser Lys Lys Glu
580 585 590
Gly Ala Glu Leu Gly Pro Ala Val Leu Phe Phe Gly Cys Arg Asn Arg
595 600 605
Gln Met Asp Tyr Ile Tyr Gln Asp Glu Leu Asp Asn Phe Leu Glu Ala
610 615 620
Gly Ala Leu Ser Glu Leu Val Val Ala Phe Ser Arg Glu Gly Pro Asn
625 630 635 640
Lys Glu Tyr Val Gln His Lys Met Ser Glu Lys Ala Ala Asp Ile Trp
645 650 655
Asn Met Ile Ser Gln Gly Gly Tyr Val Tyr Val Cys Gly Asp Ala Lys
660 665 670
Gly Met Ala Arg Asp Val His Arg Thr Leu His Ile Ile Ala His Asp
675 680 685
Gln Gly Ser Leu Asp Asn Ser Lys Ala Glu Ser Leu Val Lys Asn Leu
690 695 700
Gln Thr Thr Gly Arg Tyr Leu Arg Asp Val Trp
705 710 715
<210> 6
<211> 2148
<212> DNA
<213> Anisodus acutangulus
<400> 6
atggagtcga catcagaaaa gctttctcct tttgatttta tggcagcaat ctttaaggga 60
ggaaagatat ttgataaact gaactcgtca ttagattctg gtgactcaag ttcatcagct 120
tcattggcag ctttgttgat ggagaacaaa gatttgatga tgatattgac aacctcggtt 180
gctgttttaa ttggctgtgc agttgtgttg atgtggcggc gctcctcgac atctgctaag 240
aaagtcatgg agccaaccaa gttggtggtt cctaagtcgg ttatagaacc tgaagatatt 300
aatgatggca agaagaaaat taccatcttt ttcggaaccc agactggtac agcagagggc 360
ttcgcaaagg cacttgctga ggaagccaag gccagatatg acaaggctac ctttaaagtg 420
attgatatgg atgattatgc ggctgatgat gaagagtatg aagagaaatt gaagaaagaa 480
acattcgcat tctttttctt ggcgacatat ggagatggtg aaccaactga taacgctgcc 540
agattctata agtggtttgt agagggaaaa gagaggggtg actacttcaa gaatcttcag 600
tatggagtat ttgggcttgg taacagacaa tacgagcatt tcaacaagat tgctaaagtt 660
gtggatgaac ttctggttga gcaaggtgga cagaggcttg ttccagtggg tcttggagat 720
gatgaccaat gcattgaaga tgatattact gcatggcgtg aattactgtg gcctgaattg 780
gataaggtgc ttcttgatgg ggatgatgca actgctgcaa ctccatatac tgctgcagtt 840
ttggaatata gggttgttat ccatgaaaag tccagctttg ataatgactt gactaccgca 900
aatggtcatg caaatggaca tgtcattgtt gatgctcaac atccttgcag agctaatgtt 960
gctgttagga aggaacttca cactcctgct tctgatcgtt cttgcactca tctggagttt 1020
gacattcctg gcactggact tgcgtatgaa actggtgatc atgttggtgt gtactgtgaa 1080
aattttattg aaaccgtgga ggaagctgaa aggttactta acatatcgcc agacactttc 1140
ttttccattc acactgataa agaggatggc acaccacttg gtggaagctc attgccatct 1200
cccttccctc cttgcacttt gagaacggca ttgactcggt atgctgatct tttgagttct 1260
cctaaaaagt ctgctttact tactttagcg gcatttgctt ctgatccaaa tgaagctgat 1320
cgattacgat atcttgcatc acccgctgga aaggaagaat atgctcagtg gataattgca 1380
agtcagagaa gccttcttga agtcatggct gaatttcctt cagccaagcc ttcagtcggt 1440
gttttctttg cttctgttgc tcctcgccta caaccgagat tctactctat ctcatcatct 1500
cctaggatgg cgccatctag gattcatgtc acttgtgcac tggtttacga caaaatgcca 1560
actggacgag ttcacaaggg tgtctgctca acatggatga agaacgctat tcctctagaa 1620
gaaagccttt cctgcagtac ggcacctatt tttgttcggc aatcaaactt taaacttcca 1680
gctgataaca agattccaat cataatgatt ggccctggta ctgggttggc accattcagg 1740
ggtttcctcc aggaaagatt agcttcgaag aaggaaggag ccgagcttgg tcctgcagtg 1800
ttattttttg gatgcaggaa ccgccaaatg gactacatct atcaagatga gttagacaat 1860
ttcctcgagg ctggtgcact ttctgagcta gttgttgctt tctcacgtga aggacctaac 1920
aaagaatacg tgcaacataa aatgtcagag aaggctgcgg acatctggaa catgatttct 1980
cagggaggat atgtatatgt atgcggtgat gctaaaggca tggctaggga tgtccatcgg 2040
actcttcaca ttattgcgca cgatcaggga tcacttgaca actccaaggc tgagagtttg 2100
gtgaagaact tgcaaacgac tggaagatat ctgcgtgatg tgtggtga 2148
<210> 7
<211> 686
<212> PRT
<213> Anisodus acutangulus
<400> 7
Met Glu Ser Ser Ser Glu Leu Val Arg Ser Val Glu Ser Ala Ile Gly
1 5 10 15
Val Ser Leu Gly Ser Asp Thr Val Leu Val Leu Leu Thr Thr Ser Phe
20 25 30
Ala Val Ile Val Gly Leu Ile Val Leu Phe Phe Lys Arg Ser Ser Asp
35 40 45
Arg Ser Lys Glu Val Lys Pro Val Val Phe Pro Lys Ser Leu Gln Val
50 55 60
Glu Pro Glu Glu Glu Thr Glu Pro Glu Pro Gly Lys Val Lys Val Thr
65 70 75 80
Val Phe Phe Gly Thr Gln Thr Gly Thr Ala Glu Gly Phe Ala Lys Ala
85 90 95
Leu Ser Glu Glu Ile Lys Ala Arg Tyr Glu Lys Ala Val Val Lys Val
100 105 110
Val Asp Met Asp Asp Tyr Ala Ala Asp Asp Glu Leu Tyr Glu Glu Lys
115 120 125
Leu Lys Lys Glu Thr Val Ala Phe Phe Met Val Ala Thr Tyr Gly Asp
130 135 140
Gly Glu Pro Thr Asp Asn Ala Ala Arg Phe Tyr Lys Trp Phe Thr Glu
145 150 155 160
Gly Gln Glu Arg Gly Ala Trp Leu Gln His Leu Thr Tyr Gly Val Phe
165 170 175
Gly Leu Gly Asn Arg Gln Tyr Glu His Phe Asn Lys Ile Gly Lys Val
180 185 190
Ile Asp Glu Gln Leu Ser Glu Gln Gly Ala Lys Arg Leu Val Pro Val
195 200 205
Gly Leu Gly Asp Asp Asp Gln Cys Ile Glu Asp Asp Phe Ala Ala Trp
210 215 220
Arg Glu Gln Leu Trp Pro Glu Leu Asp Gln Ile Leu Lys Asp Glu Asp
225 230 235 240
Asp Ala Asn Ser Ala Ala Thr Pro Tyr Thr Ala Ala Ile Pro Glu Tyr
245 250 255
Arg Leu Val Ile His Asp Thr Thr Met Ser Leu Glu Asp Lys His Ala
260 265 270
Asn Met Ala Asn Gly Asn Thr Thr Tyr Asp Ile His His Pro Cys Lys
275 280 285
Val Asn Val Ala Ile Gln Arg Glu Leu His Thr Pro Glu Ser Asp Arg
290 295 300
Ser Cys Leu His Leu Glu Phe Asp Ile Ser Gly Thr Gly Ile Ser Tyr
305 310 315 320
Glu Thr Gly Asp His Val Gly Val Tyr Ala Glu Asn Ser Glu Glu Thr
325 330 335
Val Glu Glu Ala Ala Arg Leu Leu Gly Gln Ser Leu Asp Leu Val Phe
340 345 350
Ser Ile His Thr Asp Lys Glu Asp Gly Thr Ser Val Gly Gly Ser Leu
355 360 365
Pro Pro Pro Phe Pro Gly Pro Cys Thr Leu Arg Ala Ala Leu Ala Arg
370 375 380
Tyr Thr Asp Leu Leu Asn Pro Pro Arg Lys Ala Thr Leu Val Ala Leu
385 390 395 400
Ala Ala His Ala Ala Glu Pro Ser Glu Ala Glu Lys Leu Lys Phe Leu
405 410 415
Ala Ser Pro Gln Gly Lys Asp Glu Tyr Ser Gln Trp Ile Val Ala Ser
420 425 430
Gln Arg Ser Leu Val Glu Val Met Ala Glu Phe Pro Ser Ala Lys Pro
435 440 445
Pro Leu Gly Val Phe Phe Ala Ala Val Ala Pro Arg Leu Gln Pro Arg
450 455 460
Tyr Tyr Ser Ile Ser Ser Ser Pro Arg Phe Ala Pro Ala Arg Val His
465 470 475 480
Val Thr Cys Ala Leu Val Tyr Gly Pro Thr Pro Thr Gly Arg Ile His
485 490 495
Lys Gly Val Cys Ser Thr Trp Met Lys Asn Ala Val Pro Leu Lys Lys
500 505 510
Ser His Asn Cys Ser Ser Ala Pro Ile Phe Ile Arg Pro Ser Asn Phe
515 520 525
Lys Leu Pro Ala Asp Pro Ser Ile Pro Ile Val Met Val Gly Pro Gly
530 535 540
Thr Gly Leu Ala Pro Phe Arg Gly Phe Leu Gln Glu Arg Ala Ala Leu
545 550 555 560
Lys Glu Asp Gly Ala Gln Leu Gly Pro Ala Leu Leu Phe Phe Gly Cys
565 570 575
Arg Asn Arg Arg Thr Asp Phe Ile Tyr Glu Glu Glu Leu Gln Ser Phe
580 585 590
Val Asp Gln Gly Val Ile Ser Glu Leu Ile Ile Ala Phe Ser Arg Glu
595 600 605
Gly Pro Gln Lys Glu Tyr Val Gln His Lys Met Met Glu Lys Ala Ser
610 615 620
Gln Val Trp Ser Ser Ile Ser Gln Glu Gly Tyr Leu Tyr Val Cys Gly
625 630 635 640
Asp Ala Lys Gly Met Ala Arg Asp Val His Arg Thr Leu His Thr Ile
645 650 655
Val Gln Glu Gln Glu Lys Ala Asp Ser Thr Lys Ala Glu Ala Ile Val
660 665 670
Lys Lys Leu Gln Met Asp Gly Arg Tyr Leu Arg Asp Val Trp
675 680 685
<210> 8
<211> 2061
<212> DNA
<213> Anisodus acutangulus
<400> 8
atggagtcga gttcggagtt ggtgagatcg gttgaatcgg caatcggggt atcattaggg 60
agcgatacgg tgttagtgct acttacgacg tcgtttgcgg tcatcgtagg gttaattgtg 120
ttgtttttta agagatcaag tgatcggagt aaagaagtga agcctgttgt gttcccgaag 180
tcgttacaag tggagccgga ggaggaaact gagccagaac ctggaaaagt taaggtcaca 240
gtgtttttcg gtactcaaac tggtactgct gagggttttg ccaaggcttt atcagaggag 300
ataaaagcaa gatatgagaa ggcagttgtg aaagttgtgg acatggatga ttatgctgcc 360
gatgatgagc tttacgagga gaagctgaag aaagaaacag ttgcattttt catggtggca 420
acctacgggg atggcgagcc aactgataat gctgcaaggt tttacaagtg gttcactgag 480
ggacaagaac ggggtgcgtg gctgcagcac cttacctatg gcgtttttgg cctgggtaat 540
cgccaatatg aacacttcaa caagattggg aaggtgatag atgaacaatt gagtgaacaa 600
ggtgcaaaac gtcttgtgcc tgttggcctt ggtgatgatg atcagtgcat tgaagatgat 660
tttgctgcct ggcgagaaca attatggcca gaattggatc aaatacttaa agacgaggat 720
gatgcaaatt ctgcagccac tccatataca gctgcaattc ctgaatatcg tttggttatc 780
catgatacca ctatgagtct tgaggataag catgcaaaca tggctaatgg aaataccaca 840
tatgacatcc accatccatg caaagtaaat gttgctattc aaagagagct tcacacacct 900
gagtctgatc gctcatgttt acatttggag tttgatatat ctggcactgg gatttcctat 960
gaaacaggag atcatgtggg tgtttatgct gaaaattctg aagaaactgt tgaagaagct 1020
gcgagattgc tggggcagtc attagattta gtattctcta ttcataccga caaggaggat 1080
ggtacatctg ttggaggctc gttaccccca ccttttcctg gtccttgcac tctgcgtgcg 1140
gcacttgctc gttacacaga tcttctgaat cctccacgga aggctacttt ggttgcattg 1200
gctgcccatg cagctgaacc tagtgaagca gaaaagctca agttcttggc atctccacag 1260
ggcaaggacg agtattctca atggattgtt gcaagtcaaa gaagtcttgt tgaagtaatg 1320
gctgagttcc cttcggcgaa gcctcccctt ggtgtatttt ttgcagcagt tgctcctcgt 1380
ttacagcctc gttattattc aatctcgtca tctcctcgat ttgcacctgc tagagtccat 1440
gtgacctgtg cactagtcta tggtccaaca cctactggcc gaattcataa aggagtgtgt 1500
tcgacttgga tgaagaatgc agttcctttg aagaaaagtc acaattgcag ctctgctccc 1560
attttcatta ggccatctaa tttcaaacta ccggctgacc cttcaattcc aattgtcatg 1620
gtggggcctg gtactggctt ggcaccattt aggggattcc tacaggaaag agcagctttg 1680
aaggaagatg gggctcaact cggtcctgct ttgttgtttt tcggttgtag gaatcgtaga 1740
acggatttta tttatgagga ggagcttcag agttttgtgg atcaaggtgt aatatcagag 1800
ctgattattg ccttttcaag ggaagggccg cagaaagagt atgtacaaca taaaatgatg 1860
gaaaaggctt cccaggtttg gagttcaatc tcccaggagg gatatctata tgtatgtggg 1920
gatgcaaaag ggatggccag agacgttcat cgtacactcc ataccatagt ccaggagcag 1980
gagaaggccg actcaaccaa agcagaggct attgtgaaga aactccaaat ggatggaaga 2040
tatctcaggg atgtgtggtg a 2061

Claims (12)

1.一种分离的多肽,所述多肽的氨基酸序列是SEQ ID NO:1。
2.分离的多核苷酸,所述多核苷酸编码如权利要求1所述的多肽。
3.如权利要求2所述的多核苷酸,其特征在于,其核苷酸序列如SEQ ID NO:2所示。
4.包含如权利要求2所述多核苷酸的载体。
5.一种用于表达如权利要求1所述多肽的微生物,其特征在于,所述微生物转化了如权利要求4所述载体。
6.如权利要求5所述的微生物,其特征在于,所述微生物选自大肠杆菌、毕赤酵母、酿酒酵母、解脂耶氏酵母、枯草杆菌。
7.如权利要求1所述多肽、或者如权利要求5所述微生物在制备托品酮中的应用。
8.如权利要求7所述的应用,其特征在于,以4-(1-甲基-2-吡咯烷基)-3-氧代丁酸为底物原料,在如权利要求1所述多肽和细胞色素P450还原酶的联合催化下进行反应来制备托品酮。
9.如权利要求8所述的应用,其特征在于,所述细胞色素P450还原酶的氨基酸序列为SEQ ID NO:3、SEQ ID NO:5或者SEQ ID NO:7。
10.如权利要求9所述的应用,其特征在于,编码细胞色素P450还原酶SEQ ID NO:3的基因是SEQ ID NO:4;编码细胞色素P450还原酶SEQ ID NO:5的基因是SEQ ID NO:6;编码细胞色素P450还原酶SEQ ID NO:7的基因是SEQ ID NO:8。
11.如权利要求8所述的应用,其特征在于,所述权利要求1的多肽和细胞色素P450还原酶在同一个微生物中共表达;或者在不同的微生物中分别表达。
12.如权利要求8所述的应用,其特征在于,反应体系中还添加有二硫苏糖醇和NADPH。
CN201910299176.4A 2019-04-15 2019-04-15 三分三p450酶及其在制备托品酮中的应用 Active CN111826355B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910299176.4A CN111826355B (zh) 2019-04-15 2019-04-15 三分三p450酶及其在制备托品酮中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910299176.4A CN111826355B (zh) 2019-04-15 2019-04-15 三分三p450酶及其在制备托品酮中的应用

Publications (2)

Publication Number Publication Date
CN111826355A CN111826355A (zh) 2020-10-27
CN111826355B true CN111826355B (zh) 2021-11-26

Family

ID=72915541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910299176.4A Active CN111826355B (zh) 2019-04-15 2019-04-15 三分三p450酶及其在制备托品酮中的应用

Country Status (1)

Country Link
CN (1) CN111826355B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113307884B (zh) * 2021-05-25 2022-04-29 西南大学 托品酮生物合成融合蛋白及其应用和方法
CN114292825B (zh) * 2021-12-17 2023-08-18 武汉大学 一种托品酮的合成方法
CN114317631B (zh) * 2021-12-17 2023-11-07 武汉大学 单胺氧化酶在制备托品酮中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1612929A (zh) * 2001-07-12 2005-05-04 巴斯福植物科学有限公司 分离自展叶剑叶藓的 c y p 7 4酶家族之丙二烯氧化物合酶和二乙烯基醚合酶和编码这些合酶的核苷酸序列以及产生病原体抗性植物的方法
CN1690208A (zh) * 2004-04-28 2005-11-02 上海人类基因组研究中心 一种新的马尔尼菲青霉菌甘露糖脱氢酶、其编码序列及其应用
CN101085987A (zh) * 2006-06-09 2007-12-12 华北制药集团新药研究开发有限责任公司 一种l-山梨糖脱氢酶及其编码基因与应用
WO2008144073A1 (en) * 2007-05-21 2008-11-27 Teva Pharmaceutical Industries Ltd. Enzymatic process for the preparation of paliperidone and its intermediate cmhtp
CN108624603A (zh) * 2018-03-30 2018-10-09 河北省科学院生物研究所 一种(s)-羰基还原酶及其编码基因与应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1612929A (zh) * 2001-07-12 2005-05-04 巴斯福植物科学有限公司 分离自展叶剑叶藓的 c y p 7 4酶家族之丙二烯氧化物合酶和二乙烯基醚合酶和编码这些合酶的核苷酸序列以及产生病原体抗性植物的方法
CN1690208A (zh) * 2004-04-28 2005-11-02 上海人类基因组研究中心 一种新的马尔尼菲青霉菌甘露糖脱氢酶、其编码序列及其应用
CN101085987A (zh) * 2006-06-09 2007-12-12 华北制药集团新药研究开发有限责任公司 一种l-山梨糖脱氢酶及其编码基因与应用
WO2008144073A1 (en) * 2007-05-21 2008-11-27 Teva Pharmaceutical Industries Ltd. Enzymatic process for the preparation of paliperidone and its intermediate cmhtp
CN108624603A (zh) * 2018-03-30 2018-10-09 河北省科学院生物研究所 一种(s)-羰基还原酶及其编码基因与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
tropinone synthase CYP82M3 [Atropa belladonna];Bedewitz,M.A.等;《GenBank》;20181113;LOCUS、AUTHORS、ACCESSION、ORIGIN部分 *

Also Published As

Publication number Publication date
CN111826355A (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
CN111826355B (zh) 三分三p450酶及其在制备托品酮中的应用
CN111718915B (zh) 一种烟酰胺磷酸核糖转移酶突变体、包含该突变体的重组表达载体和重组菌及应用
CN108728421B (zh) 一种羰基还原酶突变体及其用途
CN109055324B (zh) 一种改进的酮还原酶及其应用
CN112877307B (zh) 一种氨基酸脱氢酶突变体及其应用
CN102373230A (zh) 某种梭菌d-塔格糖3-差向异构酶的核苷酸序列及其应用
CN104894077A (zh) 烟酰胺腺嘌呤二核苷酸-细胞色素p450还原酶及其应用
CN112574970B (zh) 一种烟酰胺单核苷酸腺苷转移酶突变体及其应用
CN110343728B (zh) 一种生物转化合成六氢哒嗪-3-羧酸的方法
CN113621629B (zh) 一种基于丙二酰辅酶a再生的柚皮素体外酶促合成方法
CN109706189B (zh) 一种d-手性肌醇的制备方法
CN110484519A (zh) 毕赤酵母翻译相关因子Bcy1在外源蛋白表达中的应用
CN114908129B (zh) 用于制备(r)-4-氯-3-羟基丁酸乙酯的脱氢酶
CN112831532B (zh) 一种酶促合成d-亮氨酸的方法
CN116790545A (zh) 用于重楼皂苷生物合成的糖基转移酶PpUGT2
CN109182286B (zh) 一种改进的氰基还原酶及其在合成3-氯吡嗪-2甲胺中的应用
CN113684191A (zh) 梨头霉甾体11β-羟化酶CYP5311B2突变体构建及其应用
KR20220039887A (ko) 메탄 및 자일로스를 동시 대사하는 메탄자화균의 개발 및 이를 이용한 시노린 생산방법
CN111808830A (zh) 一种微生物降解植物甾醇生产雄二烯二酮的方法
CN114341350A (zh) 用于制备熊脱氧胆酸的方法
CN111826357B (zh) 三分三非典型iii型聚酮合酶及其应用
CN113088500A (zh) 一种谷氨酸脱氢酶突变体、编码基因及制备l-草铵膦的方法
CN114606212B (zh) 一种圆锥铁线莲来源的香豆素合酶、基因、载体及其应用
CN110591933A (zh) 一种高效利用木糖发酵生产乙醇和木糖醇的工程菌株
CN114621965B (zh) 一种3-甾酮-δ1-脱氢酶突变体及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant